Lazard Asset Management LLC Ironwood Pharmaceuticals Inc Transaction History

Lazard Asset Management LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$8.32 - $15.45 $7,155 - $13,287	-860 Reduced 5.58%	14,542 $126,000
Q4 2023 Feb 14, 2024	BUY	$8.79 - $11.51 $96 - $126	11 Added 0.07%	15,402 $176,000
Q3 2023 Nov 14, 2023	BUY	$8.25 - $11.35 $72,426 - $99,641	8,779 Added 132.77%	15,391 $148,000
Q2 2023 Aug 14, 2023	BUY	$10.1 - $11.6 $65,680 - $75,434	6,503 Added 5966.06%	6,612 $70,000
Q1 2023 May 15, 2023	SELL	$10.37 - $12.56 $111,778 - $135,384	-10,779 Reduced 99.0%	109 $1,000
Q4 2022 Feb 14, 2023	BUY	$9.9 - $12.43 $107,791 - $135,337	10,888 New	10,888 $134,000
Q2 2022 Aug 09, 2022	BUY	$11.05 - $12.72 $51,161 - $58,893	4,630 Added 73.84%	10,900 $125,000
Q1 2022 May 13, 2022	BUY	$10.61 - $12.88 $66,524 - $80,757	6,270 New	6,270 $78,000
Q4 2021 Feb 09, 2022	SELL	$10.86 - $13.95 $42,582 - $54,697	-3,921 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.92 - $13.92 $46,738 - $54,580	3,921 New	3,921 $51,000
Q1 2021 May 14, 2021	SELL	$9.04 - $11.86 $697,887 - $915,592	-77,200 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$9.05 - $12.2 $324,180 - $437,016	35,821 Added 86.57%	77,200 $878,000
Q3 2020 Nov 13, 2020	BUY	$8.99 - $10.74 $371,997 - $444,410	41,379 New	41,379 $372,000
Q2 2020 Aug 13, 2020	SELL	$9.14 - $11.97 $78,019 - $102,175	-8,536 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$8.58 - $14.01 $42,573 - $69,517	4,962 Added 138.84%	8,536 $86,000
Q4 2019 Feb 13, 2020	BUY	$8.22 - $14.0 $17,270 - $29,414	2,101 Added 142.63%	3,574 $47,000
Q3 2019 Nov 14, 2019	BUY	$8.59 - $10.96 $12,653 - $16,144	1,473 New	1,473 $12,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $562M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.